Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
06 janv. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
16 déc. 2019 07h30 HE
|
Kura Oncology, Inc.
– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first...
Kura Oncology to Participate in Piper Jaffray Healthcare Conference
26 nov. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Present at Stifel Healthcare Conference
12 nov. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
06 nov. 2019 09h06 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
05 nov. 2019 16h05 HE
|
Kura Oncology, Inc.
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted...
Kura Oncology Appoints James Basta as Chief Legal Officer
04 nov. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Report Third Quarter 2019 Financial Results
30 oct. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
29 oct. 2019 11h50 HE
|
Kura Oncology, Inc.
– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% – – Median progression-free survival of 6.1 months vs. 2.8 months on last prior therapy – ...
Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
23 oct. 2019 16h05 HE
|
Kura Oncology, Inc.
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th – – Previously announced poster...